Ocugen (OCGN) EBITDA (2014 - 2026)
Ocugen (OCGN) posted EBITDA of -$17.8 million for Q1 2026, down 4.97% on a QoQ basis from -$17.0 million in Q4 2025, and down 23.02% year-over-year from -$23.2 million in Q1 2025.
Ocugen (OCGN) EBITDA (2014 - 2026) Analysis & Trends
Ocugen's EBITDA history runs 13 years deep, the most recent figure standing at -$17.8 million for Q1 2026.
- Quarterly EBITDA fell 23.02% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.3 million (down 16.15% YoY) and the FY2025 annual result came in at -$62.9 million, down 14.9% from the prior year.
- EBITDA was -$17.8 million for Q1 2026 at Ocugen, down from -$17.0 million in the prior quarter.
- Across five years, EBITDA topped out at -$11.5 million in Q4 2023 and bottomed at -$25.1 million in Q3 2022.
- A 5-year average of -$17.1 million and a median of -$17.0 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA sank 169.66% — and 2023, when it surged 50.65%.
- Ocugen's EBITDA stood at -$23.4 million in 2022, then surged by 50.65% to -$11.5 million in 2023, then retreated by 20.09% to -$13.8 million in 2024, then dropped by 22.8% to -$17.0 million in 2025, then declined by 4.97% to -$17.8 million in 2026.
- Business Quant data shows OCGN's EBITDA at -$17.8 million in Q1 2026, -$17.0 million in Q4 2025, and -$17.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Ocugen | 399.60 Mn | 399.60 Mn | - | -17.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.84 Mn |
| Dec 31, 2025 | -17.00 Mn |
| Sep 30, 2025 | -17.63 Mn |
| Jun 30, 2025 | -13.80 Mn |
| Mar 31, 2025 | -14.50 Mn |
| Dec 31, 2024 | -13.84 Mn |
| Sep 30, 2024 | -13.25 Mn |
| Jun 30, 2024 | -15.45 Mn |
| Mar 31, 2024 | -12.22 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Sep 30, 2023 | -12.43 Mn |
| Jun 30, 2023 | -23.54 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -23.36 Mn |
| Sep 30, 2022 | -25.11 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.57 Mn |
| Sep 30, 2021 | -10.79 Mn |
| Jun 30, 2021 | -25.61 Mn |